in various biological processes including tumorigenesis in a wide range of cancers containing glioma. 7, 8 For instance, the SNHG5/ miR-32 axis regulates gastric cancer cell proliferation and migration by targeting KLF4. 9 Long non-coding RNA HOXA-AS2 regulates malignant glioma behaviours via the MiR-373/EGFR axis. 10 CRNDE promotes malignant progression of glioma by attenuating miR-384/ PIWIL4/STAT3 axis. 11 MATN1 antisense RNA 1(MATN1-AS1), a newfound lncRNA that locates in 1p35.2, has been recognized to be non-significantly downregulated in ischaemic stroke. 12 However, the function of MATN1-AS1 needs to be discovered.
Competing endogenous RNAs (ceRNAs), which also celebrated as miRNA "sponges" or miRNA "decoy" that firstly identified in plants and named "target mimicry" process, 13 are a class of RNA transcripts that competitively binding to the common miRNA via the base complementary with miRNA response elements (MREs), thereby reducing the amount of miRNAs targeting messenger RNAs (mRNAs). [14] [15] [16] Recently, many lncRNAs have been found to function in cancers through such mechanism. For example, lncRNA SPRY4-IT1 sponges miR-101-3p to promote proliferation and metastasis of bladder cancer cells through upregulating EZH2. 17 Long non-coding RNA UICLM promotes colorectal cancer liver metastasis by acting as a ceRNA for microRNA-215 to regulate ZEB2 expression. 18 Nevertheless, it remains covered whether MATN1-AS1 could also implicate in a ceRNA network in glioma.
In this study, we first discover that MATN1-AS1 may play a significant role in glioma after analysing TCGA database. Then, potential miRNAs that might have interactions with MATN1-AS1 are screened using online tools starBase 2.0, and miR-200b/c/429 from miR-200 family is found out. Based on this, we aim to investigate the role and function of MATN1-AS1 in glioma and identify whether it affects glioma by functioning as ceRNA for miR-200b/c/429.
| MATERIAL S AND ME THODS

| Clinical samples
Clinical samples (n = 80) were collected from patients with glioma who underwent operations in the Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Jiao Tong University School of Medicine. All of these patients suffered no any treatment before surgery. The clinicopathologic features of each patient were also collected in Table 1 . The using of human tissues in this study was approved by the Ethics Committee of the Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, and the informed consent had been signed by all of the patients before our study.
| Cell lines and cell culture
Human glioma cell lines (T98G, LN229, U87 and U251) and human embryonic kidney cell line HEK-293T were purchased from the American Type Culture Collection (ATCC, USA), while the normal human astrocytes (NHAs) were obtained from ScienCell Research Laboratories (Carlsbad, CA, USA). All of the cells were grown in DMEM (Dulbecco's modified Eagle's medium) with 10% FBS (foetal bovine serum; Gibco, USA) and maintained in a humid atmosphere with 5% CO 2 at 37℃.
| Cell transfection
The specific shRNAs against MATN1-AS1 and corresponding control shRNA (sh-NC) as well as sh-CHD1 and its control were obtained from Santa Cruz Biotechnology Inc (Dallas, TX, USA). Similarly, III transcriptase (Invitrogen, Grand Island, NY). qRT-PCR was carried out in a Bio-Rad CFX96 system, and SYBR Green was utilized to examine the mRNA level of genes. To normalize the expression of genes, GAPDH was used as a control in this study. All experiments were performed for at least three times.
| RNA extraction and qRT-PCR
| Cell proliferation assay
Cells were seeded into 24-well plates at a density of 3000 cells/well and cultured for 24, 48, 72 and 96 hours. Then, culture solution containing MTT was used to replace the medium, and DMSO was applied to melt the blue crystals. At last, cell viability was estimated by detecting the absorbance at 490 nm. All tests were carried out in triplicate.
For colony formation assay, cells with a concentration of 1 × 10 3 cells/well were seeded into six-well plates and cultured in DMEM supplemented with 10% FBS at 37℃. After incubated for two weeks, cells were washed using PBS and fixed with methanol followed by staining with 1% crystal violet. Thereafter, the number of colonies was counted manually. All tests were carried out in triplicate.
| Flow cytometry analysis
After incubation for two days, the harvested cells were used for following experiments. For analysis of cell cycle, cells were fixed by 75% ethanol and then stained using PI (BD Biosciences). FACScan was applied to analyse the stained cells, and then, the proportion of cells in different cell cycle phases (G0/G1, G2/M and S) were calculated.
In cell apoptosis analysis, apoptosis rate of transfected cells was evaluated by using Annexin V-APC/PI apoptosis detection kit (KeyGEN) following the manufacturer's instruction and then analysed using FACScan. All tests are carried out in triplicate.
| In vivo experiment
The male nude mice at the age of 4 weeks were obtained from the 
| Immunohistochemistry (IHC) staining
Paraffin sections made from tumours obtained from in vivo experiments were used for immunohistochemistry assays to detect protein expression levels of Ki67 proteins. In accordance with the manufacturer's introduction, tissue sections stained immunohistochemically are determined separately by two pathologists using the indirect streptavidin-peroxidase method. The primary antibodies against Ki67 (#9449, Cell Signaling Technology, Danvers, MA, USA) and
horseradish peroxidase-conjugated IgG were used in this study.
Then, the proteins were visualized in situ by the use of 3, 3-diaminobenzidine kit (BioGenex, Fremont, CA, USA).
| Luciferase reporter assay
Firstly, pmirGLO-MATN1-AS1-WT or pmirGLO-MATN1-AS1-mut, pmirGLO-CHD1-wt or pmirGLO-CHD1-mut was constructed using a The relative luciferase activity was determined by a dual-luciferase reporter assay kit (Promega) after 48 hours of transfection.
| RNA immunoprecipitation (RIP) assay
In this study, EZMagna RIP kit (Millipore, Billerica, MA, USA) was used for RNA immunoprecipitation on the basis of manufacturer's protocol. U87 and U251 cells were scraped off from the plates and dissolved in 100% RIP lysis buffer. Then, extracted cells were kept in RIP buffer, in which magnetic bead (Millipore)-incubated human anti-Ago2 antibody (Millipore) was contained. And beads with IgG were used as negative control. Moreover, the density of RNA was evaluated using a NanoDrop spectrophotometer (Thermo Scientific),
whereas the quality of RNA was assessed by bioanalyser (Agilent, Santa Clara, CA, USA). At length, the purified RNA was analysed by qRT-PCR. All tests were carried out in triplicate.
| RNA pull-down assay
RNA pull-down assays were conducted as previously described. 17 Briefly, RNAs were biotin-labelled using Biotin RNA Labeling Rochester, NY) was applied to visualize protein bands. In the end, all of the proteins were exposed to X-ray film. All experimental steps were performed for at least three times. 
| Western blot assay
| Statistical analysis
| RE SULTS
| MATN1-AS1 is highly expressed in glioma tissues and cell lines
To find out lncRNAs related to glioblastoma, data from TCGA database are initially analysed, and we observed that MATN1-AS1 level was significantly related to the outcome of patients with glioma ( Figure 1A ). Based on this, we hypothesized that MATN1-AS1 might play a key role in glioma. Thereby, we tested the expression levels of MATN1-AS1 in 80 pairs of glioma tissues and adjacent non-tumour tissues by RT-qPCR. The results showed that MATN1-AS1 Note: Proportional hazards method analysis shows a positive, independent prognostic importance of MATN1-AS1 expression (P = .010). *P < .05 is considered statistically significant.
was markedly highly expressed in glioma tissues in comparison with corresponding non-tumour tissues ( Figure 1B) . Also, MATN1-AS1 expression in glioma cell lines (T98G, LN229, U87 and U251) and normal human astrocytes (NHAs) were detected. Consistently, MATN1-AS1 was revealed to be obviously upregulated in glioma cell lines compared with NHAs ( Figure 1C ). In the light of these results,
we put a preliminary hypothesis that MATN1-AS1 might act as a carcinogenic lncRNA in glioma.
| The clinical significance of MATN1-AS1 in glioma
Next, the correlation between MATN1-AS1 expression and clinicopathological features of patients with glioma was analysed (Table I) .
Based on the cut-off value (6.24), patients with glioma were divided into the high (n = 47) or the low MATN1-AS1 expression groups (n = 33). It was showed that MATN1-AS1 expression level was apparently correlated with tumour size (P = .003), KPS (P = .001) and
WHO grade (P = .007). However, there was no statistical significance in the association between MATN1-AS1 expression and age, gender, or tumour size. In addition, the level of MATN1-AS1 could serve as an independent prognostic biomarker for glioma patients, so as some clinical features such as KPS (P = .033) and WHO grade (P = .032), while others had no impact on the prognosis (Table 2) .
Moreover, Kaplan-Meier analysis revealed that glioma patients with high levels of MATN1-AS1 usually had poor overall survival in contrast to those with low MATN1-AS1 levels ( Figure 1D ). These data indicated that MATN1-AS1 may be a novel prognostic biomarker for glioma.
| Knockdown of MATN1-AS1 affects cell proliferation and apoptosis in vitro
To study the biological role of MATN1-AS1 in glioma, MATN1-AS1 was silenced in U251 and U87 cells by transfecting with three different shRNAs (Figure 2A) . Then, MTT assay demonstrated that cell Figure 2B ). According to these two results (Figure 2A,B) , the sh-MATN1-AS1#2 was chosen for following experiments and described just as sh-MATN1-AS1 subsequently. Seen from Figure 2C , knockdown of MATN1-AS1 caused a large reduction in the number of colonies in U87 and U251 cells. Additionally, the proportion of cells arrested in G0/G1 phase were increased after silencing MATN1-AS1 in U87 and U251 cells ( Figure 2D ). Moreover, MATN1-AS1 knockdown distinctly increased the rate of cell apoptosis in both of two cells (Figure 2E ).
At last, Western blot analysis accordantly confirmed that the expression of cell cycle-associated proteins (CDK4 and Cyclin D1) and
anti-apoptotic Bcl-2 were downregulated, whereas pro-apoptotic
Bax was upregulated in U87 and U251 cells under MATN1-AS1 silence ( Figure 2F ). These results revealed that silencing MATN1-AS1
repressed cell proliferation and stimulated cell apoptosis in vitro.
| Silenced MATN1-AS1 suppresses tumour growth in vivo
On the basis of the previous observations in vitro, a tumorigenesis assay was conducted in nude mice to make sure whether silenced MATN1-AS1 inhibits tumour growth in vivo. As shown in Figure 3A ,
the formed tumours seemed to be smaller in the mice injected with U87 cells which were transduced with sh-MATN1-AS1 than in those injected with the control. Besides, the average weight of the tumours originated from MATN1-AS1 silenced U87 cells was markedly less than that of tumours originated from the sh-NC transfected cells ( Figure 3B ). Additionally, depletion of MATN1-AS1 led to a significant reduction in the tumour growth rate ( Figure 3C ).
Furthermore, the expression of Ki67, which served as an indicator of the proliferative activity of the tumour cells, was assessed by IHC staining and suggested to be remarkably decreased under MATN1-AS1 suppression ( Figure 3D ). Collectively, silencing MATN1-AS1
suppressed tumorigenesis in vivo.
| MATN1-AS1 directly targets miR-200b/c/429 in glioma cells
Since many lncRNAs have been reported to function as ceRNAs in various cancers, 19 we supposed that MATN1-AS1 may also acted as a ceRNA in glioma. First of all, the cellular location of MATN1-AS1 was measured and assessed by subcellular fractionation assay and FISH assay. It was found that MATN1-AS1 was predominantly located in the cytoplasm of glioma cells ( Figure S1A,B) . Then, we
seek out three miRNAs which belong to miR-200 family that could bind with MATN1-AS1 using online tool starBase v2.0 (http:// starb ase.sysu.edu.cn/brows eNcRNA.php) ( Figure 4A ). And we constructed the wild-type MATN1-AS1 (MATN1-AS1-Wt) which contained the binding sites with miR-200b/c/429 and mutant MATN1-AS1 (MATN1-AS1-Mut) without binding sites ( Figure 4B) .
Then, the luciferase reporter assay indicated that only the luciferase activity of MATN1-AS1-WT but not that of MATN1-AS1-Mut is cut down by miR-200b/c/429 mimics in either U87 or U251 cells ( Figure 4C ). Besides, we revealed that both MATN1-AS1 and miR- Figure 4H ). Thus, it is suggested that MATN1-AS1
can be the sponges of miR-200b/c/429 in glioma cells.
| MATN1-AS1 regulates CHD1 by sponging miR-200b/c/429
To Figure 5D ). Additionally, pull-down assay followed by Western blot analysis was performed to determine the interaction between MATN1-AS1 and CHD1. As a result, no direct interaction between MATN1-AS1 and CHD1 was analysed ( Figure S1D ). To explore the relationship between the expression level of MATN1-AS1, miR- 
| CHD1 promotes cell proliferation and inhibits cell apoptosis in glioma cells
Due to the upregulation of CHD1 in glioma tissues and cell lines ( Figure   S2A ,B), we wondered the role of CHD1 in glioma. First of all, the Kaplan-Meier curve revealed that glioma patients with higher CHD1 expression undergo poorer overall survival than those with lower CHD1 level ( Figure 6A ). Next, we investigated its effect on the biological behaviours of glioma cells. As displayed in Figure 6B , silencing CHD1 had no influence on MATN1-AS1 expression but only decreased CHD1 level in both U87 and U251 cells, which verified that CHD1 was the downstream of MATN1-AS1. Additionally, CHD1 knockdown notably reduced cell viability and colony formation ability in both U87 and U251 cells ( Figure 6C,D) . Furthermore, the apoptotic rate of two glioma cells was markedly strengthened under CHD1 suppression ( Figure 6E ).
Together, CHD1 silence inhibited cell proliferation but enhances cell apoptosis, namely CHD1-promoted tumorigenesis in glioma. Figure 7A,B) . In addition, the increased proportion of U251 cells 
| The impact of MATN1-AS1-miR-200b/c/429-CHD1 axis on glioma cell activities
| D ISCUSS I ON
Recently, increasing evidence has identified that lncRNAs are dysregulated in multiple malignancies. [22] [23] [24] Moreover, lncRNAs also modulated biological processes in glioma, such as proliferation, apoptosis and angiogenesis. [25] [26] [27] [28] MATN1-AS1 is a newfound lncRNA which locates in 1p35.2 and has been found downregulated in ischaemic stroke. 12 In this study, we revealed that MATN1-AS1 was highly expressed in glioma tissues and cell lines, and its upregulation was closely related to poor clinical outcomes. Next, knockdown of MATN1-AS1 obviously inhibited cell proliferation in vitro and suppresses tumour growth in vivo.
In the past decade, growing evidence has demonstrated that cytoplasmic lncRNAs could function as "RNA sponges" or ceRNAs to bind with miRNAs, and thereby, the regulatory effects of miRNAs on target mRNAs would be hampered. 11, 19 All these reports indicated that there are interactions between miRNAs, lncRNAs and mRNAs in tumours.
What's more, it is also elucidated that lncRNAs would influence the progression by sponging miRNAs even in glioma. in indicated U251 cells were tested by flow cytometry analysis. E, Western blot analysis was conducted in transfected U251 cells to further validate above results. Data are obtained from at least three experiments for mean ± SD. *P < .05, **P < .01 compared with controls and cell fate. 21, 32 Here, it is screened out as the direct target of miR-200b/c/429 by using online tools. In addition, CHD1 has been researched to have different effects on different cancers. For example, CHD1 is a tumour suppressor in prostate cancer and oesophageal cancer 33, 34 while it seems to exert as an oncogene in breast cancer. 20, 35 Interestingly, Rodrigues, LU, et al uncover that loss of CHD1 promotes aggressive prostate cancer 36 ; however, Zhao, D., et al revealed that knockdown of CHD1 inhibits tumour growth of PTEN-null prostate cancer. 37 In our study, CHD1 was demonstrated to be an oncogene in glioma and positively regulated by MATN1-AS1 but negatively regulated by miR-200b/c/429 in this disease. At last, the rescue assays illustrated that MATN1-AS1 facilitates glioma progression via miR-200b/c/429-CHD1 axis. CHD1 is of considerable importance in DNA repair whose deficiency may eventually cause aberrant expression of multiple oncogenes and tumour suppressors 38 ; however, the detailed mechanism by which CHD1 regulates genes involved in glioma tumorigenesis needs to be further elucidated in the future.
To sum up, we uncovered that MATN1-AS1 elicits carcinogenesis through functioning as a ceRNA to regulate CHD1 by sponging miR-200b/c/429 in glioma for the first time, thereby indicating new targets for glioma treatment. Nevertheless, more researches need to be carried out in the future until applications.
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